Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in breast cancer cell line

Purpose: Valproic acid (VPA) is used mainly for the treatment of epilepsy and other seizure disorders, however, it is known to be one of histone deacetylase (HDAC) inhibitors. HDACIs have represented roles in radiation-sensitizing of cancer cells. This study is aimed to study to evaluate the radiose...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radiation and cancer research 2018-01, Vol.9 (2), p.86-92
Main Authors: Ahmad Yarmohamadi, Jahanbakhsh Asadi, Roghaye Gharaei, Mostafa Mir, Alireza Khoshbin Khoshnazar
Format: Article
Language:English
Subjects:
MCF-7 cell
radiosensitizer
valproic acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: Valproic acid (VPA) is used mainly for the treatment of epilepsy and other seizure disorders, however, it is known to be one of histone deacetylase (HDAC) inhibitors. HDACIs have represented roles in radiation-sensitizing of cancer cells. This study is aimed to study to evaluate the radiosensitizing capability of VPA in MCF-7 breast cancer cell line. Materials and Methods: Cell viability and apoptosis were assayed using MTT and TUNEL assays, respectively and caspase-8 and caspase-9 activities were measured by commercially available kits. Results: Our finding showed that pre treatment of cells with VPA, notably enhanced apoptotic cell death in MCF-7 cell line. Our results showed that VPA sensitizes cancer cells against radiation. Conclusion: Valproic acid could be a beneficial radio-sensitizer in breast cancer radiotherapy.
ISSN:2588-9273
2468-9203
DOI:10.4103/jrcr.jrcr_37_17